Prostate
The following list provides a brief description of prostate cancer trials that are open for recruitment in Western Australia. If you would like more information please follow the links provided, contact one of the trial sites or speak with your doctor.
Please note that this list is based on information provided to the Cancer Council by WA hospitals and may not include all clinical trials that are running in WA.
Where ‘N/A' appears - this means the lacking information has not been provided to date to the Cancer Council.
KEYNOTE-991 / MK3475-991
| Registered Title | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991) |
| Purpose | This study will assess the efficacy and safety of pembrolizumab plus enzalutamide plus ADT versus placebo plus enzalutamide plus ADT in participants with mHSPC. The primary hypothesis is that in participants with mHSPC, the combination of pembrolizumab plus enzalutamide plus ADT is superior to placebo plus enzalutamide plus ADT with respect to 1) radiographic progression-free survival (rPFS) per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by blinded independent central review (BICR) and 2) overall survival (OS). |
| Lay Summary | N/A |
| WA Trial Sites |  Cancer Centre Clinical Trials Unit Ph. 08 615 26530 |
| Links | US National Library of Medicine |
Acknowledgements: US National Library of Medicine
DASL-HiCaP (ANZUP1801)
| Registered Title | DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801): A Randomised Phase 3 Double-blind, Placebo-controlled Trial of Adding Darolutamide to Androgen Deprivation Therapy and Definitive or Salvage Radiation in Very High Risk, Clinically Localised Prostate Cancer |
| Purpose | The purpose of this study is to determine the effectiveness of darolutamide as part of adjuvant androgen deprivation therapy (ADT) with a luteinising hormone releasing hormone analogue (LHRHA) in men having radiation therapy for localised prostate cancer at very high risk of recurrence. |
| Lay Summary | N/A |
| WA Trial Sites |
|
| Links | US National Library of Medicine |
Acknowledgements: US National Library of Medicine
MAGNITUDE
| Registered Title | A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer |
| Purpose | "The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate and prednisone (AA-P) compared to AA-P plus placebo." |
| Lay Summary | N/A |
| WA Trial Sites | Cancer Centre Clinical Trials Unit Ph. 08 615 26530
|
| Links | US National Library of Medicine |
KEYNOTE 641
Hypothesis 1: The combination of pembrolizumab plus enzalutamide is superior to placebo plus enzalutamide with respect to Radiographic Progression-free Survival (rPFS) per Prostate
Acknowledgements: US National Library of Medicine
Registered Title
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
Purpose
The purpose of this study is to assess the efficacy and safety of the combination of
pembrolizumab (MK-3475) and enzalutamide in the treatment of men with metastatic
castration-resistant prostate cancer (mCRPC) who have not received chemotherapy for mCRPC,
are abiraterone-naïve, or are intolerant to or progressed on abiraterone acetate. There are
two primary study hypotheses.
enzalutamide with respect to Overall Survival (OS).
Hypothesis 2: The combination of pembrolizumab plus enzalutamide is superior to placebo plus
Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1
(RECIST 1.1) as assessed by blinded independent central review."
Lay Summary
N/A
WA Trial Sites
Cancer Centre Clinical Trials Unit Ph. 08 615 26530
Links
US National Library of Medicine
KEYLYNK-010
| Registered Title | A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Who Are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment With One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010) |
| Purpose |
The purpose of this study is to assess the efficacy and safety of the combination of the 1. Overall Survival (OS) and 2. Radiographic progression-free survival (rPFS) per Prostate Cancer Working Group |
| Lay Summary | N/A |
| WA Trial Sites | Cancer Centre Clinical Trials Unit Ph. 08 615 26530 |
| Links | US National Library of Medicine |
Acknowledgements: US National Library of Medicine
ENHA01
| Registered Title | Exploring the role of androgen receptor blockade in increasing the expression of prostate specific membrane antigen (PSMA) and enhancing 68Ga-PSMA-11-PET/CT imaging in patients with metastatic prostate cancer |
| Purpose | The purpose of this study is to determine the effect of androgen deprivation therapy, a treatment commonly prescribed in prostate cancer patients, on the effectiveness of medical imaging techniques. |
| Lay Summary | N/A |
| WA Trial Sites |  Ph. 08 6318 2871 |
| Links | Australian New Zealand Clinical Trials Registry |
Acknowledgments: Australian New Zealand Clinical Trials Registry
TRITON3
| Registered Title |
TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency |
|
Purpose |
The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel. |
|
Lay Summary |
N/A |
|
WA Trial Sites |
|
|
Links |
Ph. Acknowledgements: US National Library of Medicine
[Return to List of Clinical Trials]
